CN108245511A - 氨来占诺抑制上皮间质转化及抗肿瘤转移中的用途 - Google Patents
氨来占诺抑制上皮间质转化及抗肿瘤转移中的用途 Download PDFInfo
- Publication number
- CN108245511A CN108245511A CN201810008215.6A CN201810008215A CN108245511A CN 108245511 A CN108245511 A CN 108245511A CN 201810008215 A CN201810008215 A CN 201810008215A CN 108245511 A CN108245511 A CN 108245511A
- Authority
- CN
- China
- Prior art keywords
- cell
- amlexanox
- epithelial
- purposes
- luciferase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960003731 amlexanox Drugs 0.000 title claims abstract description 36
- SGRYPYWGNKJSDL-UHFFFAOYSA-N amlexanox Chemical compound NC1=C(C(O)=O)C=C2C(=O)C3=CC(C(C)C)=CC=C3OC2=N1 SGRYPYWGNKJSDL-UHFFFAOYSA-N 0.000 title claims abstract description 34
- 206010027476 Metastases Diseases 0.000 title claims abstract description 18
- 238000006243 chemical reaction Methods 0.000 title claims abstract description 14
- 230000009401 metastasis Effects 0.000 title claims abstract description 8
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 23
- 238000012546 transfer Methods 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 229940041181 antineoplastic drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 28
- 238000000034 method Methods 0.000 abstract description 7
- 238000012216 screening Methods 0.000 abstract description 5
- 238000002560 therapeutic procedure Methods 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 68
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 29
- 108060001084 Luciferase Proteins 0.000 description 19
- 239000005089 Luciferase Substances 0.000 description 18
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 13
- 201000011510 cancer Diseases 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 10
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 9
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 8
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 210000000981 epithelium Anatomy 0.000 description 6
- 102000013127 Vimentin Human genes 0.000 description 5
- 108010065472 Vimentin Proteins 0.000 description 5
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 5
- 210000005048 vimentin Anatomy 0.000 description 5
- 108010052090 Renilla Luciferases Proteins 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 102000000905 Cadherin Human genes 0.000 description 3
- 108050007957 Cadherin Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 2
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 206010013457 Dissociation Diseases 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 241000242739 Renilla Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- -1 amlexanox compound Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 208000018459 dissociative disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 238000011022 operating instruction Methods 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000003151 transfection method Methods 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 240000002825 Solanum vestissimum Species 0.000 description 1
- 235000018259 Solanum vestissimum Nutrition 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000002804 anti-anaphylactic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 208000020670 canker sore Diseases 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000002038 chemiluminescence detection Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000001047 purple dye Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810008215.6A CN108245511B (zh) | 2018-01-04 | 2018-01-04 | 氨来占诺抑制上皮间质转化及抗肿瘤转移中的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810008215.6A CN108245511B (zh) | 2018-01-04 | 2018-01-04 | 氨来占诺抑制上皮间质转化及抗肿瘤转移中的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108245511A true CN108245511A (zh) | 2018-07-06 |
CN108245511B CN108245511B (zh) | 2020-07-03 |
Family
ID=62725600
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810008215.6A Active CN108245511B (zh) | 2018-01-04 | 2018-01-04 | 氨来占诺抑制上皮间质转化及抗肿瘤转移中的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108245511B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110013480A (zh) * | 2019-01-07 | 2019-07-16 | 中国人民解放军第二军医大学 | 氨来呫诺在制备电离辐射致放射性肺损伤防治药物中的应用 |
CN112010852A (zh) * | 2020-08-12 | 2020-12-01 | 上海诺精生物科技有限公司 | 一类抑制PCa细胞转移的化合物及用途 |
CN112047955A (zh) * | 2020-08-12 | 2020-12-08 | 上海诺精生物科技有限公司 | 一类用于抑制前列腺癌细胞迁移的化合物 |
WO2021248767A1 (zh) * | 2020-06-12 | 2021-12-16 | 上海诺精生物科技有限公司 | 一类提高PCa耐药细胞对拮抗剂敏感性的化合物及用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014062621A1 (en) * | 2012-10-15 | 2014-04-24 | Stc.Unm | Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits |
WO2018237326A1 (en) * | 2017-06-22 | 2018-12-27 | 1AlMOONSHOT PHARMA LLC | METHODS OF TREATING CANCER USING COMPOSITIONS COMPRISING AMLEXANOX AND IMMUNOMODULATORS |
-
2018
- 2018-01-04 CN CN201810008215.6A patent/CN108245511B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014062621A1 (en) * | 2012-10-15 | 2014-04-24 | Stc.Unm | Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits |
WO2018237326A1 (en) * | 2017-06-22 | 2018-12-27 | 1AlMOONSHOT PHARMA LLC | METHODS OF TREATING CANCER USING COMPOSITIONS COMPRISING AMLEXANOX AND IMMUNOMODULATORS |
Non-Patent Citations (1)
Title |
---|
YANG LIU等: "Amlexanox, a selective inhibitor of IKBKE, generates anti-tumoral effects by disrupting the Hippo pathway in human glioblastoma cell lines", 《CELL DEATH AND DISEASE》 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110013480A (zh) * | 2019-01-07 | 2019-07-16 | 中国人民解放军第二军医大学 | 氨来呫诺在制备电离辐射致放射性肺损伤防治药物中的应用 |
WO2021248767A1 (zh) * | 2020-06-12 | 2021-12-16 | 上海诺精生物科技有限公司 | 一类提高PCa耐药细胞对拮抗剂敏感性的化合物及用途 |
CN112010852A (zh) * | 2020-08-12 | 2020-12-01 | 上海诺精生物科技有限公司 | 一类抑制PCa细胞转移的化合物及用途 |
CN112047955A (zh) * | 2020-08-12 | 2020-12-08 | 上海诺精生物科技有限公司 | 一类用于抑制前列腺癌细胞迁移的化合物 |
CN112010852B (zh) * | 2020-08-12 | 2021-09-07 | 上海诺精生物科技有限公司 | 一类抑制PCa细胞转移的化合物及用途 |
WO2022032867A1 (zh) * | 2020-08-12 | 2022-02-17 | 上海诺精生物科技有限公司 | 一类用于抑制前列腺癌细胞迁移的化合物 |
CN112047955B (zh) * | 2020-08-12 | 2023-02-28 | 上海诺精生物科技有限公司 | 一类用于抑制前列腺癌细胞迁移的化合物 |
Also Published As
Publication number | Publication date |
---|---|
CN108245511B (zh) | 2020-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108245511A (zh) | 氨来占诺抑制上皮间质转化及抗肿瘤转移中的用途 | |
Soundararajan et al. | EMT, stemness and tumor plasticity in aggressive variant neuroendocrine prostate cancers | |
Wang et al. | Combination therapy targeting both cancer stem-like cells and bulk tumor cells for improved efficacy of breast cancer treatment | |
Cariati et al. | Stem cells and breast cancer | |
CN109207428A (zh) | 循环肿瘤细胞的分离和培养方法 | |
Patel et al. | Challenges in the development of future treatments for breast cancer stem cells | |
CN106987555A (zh) | 高效诱导人多能干细胞向心肌细胞分化的小分子化合物组合物 | |
CN114032277B (zh) | 一种基于染色法的肿瘤类器官药物敏感性检测方法 | |
Lucky et al. | Patient-derived nasopharyngeal cancer organoids for disease modeling and radiation dose optimization | |
CN107419004A (zh) | lncRNA‑RP11‑290F20.3及其小干扰RNA的应用 | |
CN114426949B (zh) | 一种建立胰腺或胰腺癌类器官的培养基及方法和应用 | |
Uloza et al. | Effect of laryngeal squamous cell carcinoma tissue implantation on the chick embryo chorioallantoic membrane: morphometric measurements and vascularity | |
Yap et al. | Pluripotent stem cell-derived committed cardiac progenitors remuscularize damaged ischemic hearts and improve their function in pigs | |
Eyol et al. | Few genes are associated with the capability of pancreatic ductal adenocarcinoma cells to grow in the liver of nude rats | |
WO2023217128A1 (zh) | 胃粘膜上皮前体样细胞及其制备方法和应用 | |
Cui et al. | Evaluating glioblastoma tumour sphere growth and migration in interaction with astrocytes using 3D collagen-hyaluronic acid hydrogels | |
CN108113987A (zh) | 离子泵抑制剂抑制上皮间质转化及抗肿瘤转移中的用途 | |
US11628187B2 (en) | Spalax fibroblast-derived anti-cancer agents | |
CN110177868A (zh) | 用于癌症干细胞(csc)扩增的方法 | |
Gostjeva et al. | Metakaryotic cancer stem cells are constitutively resistant to X-rays and chemotherapeutic agents, but sensitive to many common drugs | |
CN115501345B (zh) | Acat1基因或蛋白在调控结直肠癌细胞增殖和转移中的应用 | |
CN110393716A (zh) | 防己诺林碱在制备抑制肺癌转移的药物中的应用 | |
Milne et al. | Modelling esophageal adenocarcinoma and Barrett’s esophagus with patient-derived organoids | |
Yang et al. | Surgical and pathological outcomes of complete mesocolic excision compared with conventional surgery in right colon cancers | |
WO2024065883A1 (zh) | 一种用于鼻咽癌类器官培养的培养基、及其培养方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190328 Address after: Room 501, Building 333 Guiping Road, Xuhui District, Shanghai, 2003 Applicant after: Shanghai Norgin Biotechnology Co.,Ltd. Address before: Room C28, Building 6, 3, 4299 Jindu Road, Minhang District, Shanghai 201108 Applicant before: CHUNKUI BIOTECHNOLOGY (SHANGHAI) Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240301 Address after: 200233, Room B3, 1st to 3rd Floor, No. 217-225 Hongcao South Road, Xuhui District, Shanghai Patentee after: Shanghai Qianju Biopharmaceutical Co.,Ltd. Country or region after: China Address before: Room 501, Building 333 Guiping Road, Xuhui District, Shanghai, 2003 Patentee before: Shanghai Norgin Biotechnology Co.,Ltd. Country or region before: China |
|
TR01 | Transfer of patent right |